Powering the Future of Drug Development
Outpacing disease is at the heart of our investment strategy. We invest in companies developing breakthrough therapies that address significant unmet medical needs, as well as in the technologies, tools and services that improve the way medicines are discovered, developed, manufactured and delivered.
Our investment focus includes novel therapeutics, digital health and AI, life science tools, pharma services and advanced manufacturing.
We typically invest from seed through early growth stages across Europe and the US, with a particular interest in companies connected to the rapidly evolving Greek life sciences ecosystem.
Rhea Connects
We believe the next generation of life sciences leaders will be built across borders, not within them.
Drawing on decades of VC investment track record, company building and board experience across Europe and the US, Rhea combines an international network with privileged access to the rapidly emerging Greek innovation ecosystem.
We back ambitious teams by anticipating the evolving needs of the pharmaceutical industry and equipping entrepreneurs with the talent, expertise and tools developed across the world’s leading innovation hubs and industry leaders.
Through focused strategic dealmaking and collaboration with like-minded specialist investors, we help transform scientific breakthroughs into real-world impact.
How We Invest
We invest with discipline and support with conviction. Every investment opportunity undergoes a rigorous evaluation of its scientific foundation, competitive potential and execution capability.
Once we are convinced, we become a committed long-term partner. Beyond capital, we provide strategic guidance and leverage our international network, industry relationships and investment experience to help companies achieve key scientific, commercial and financing milestones while building sustainable long-term value.
Backed by Leading Institutional and Strategic Investors
Rhea BioVentures combines the financial strength of leading institutional investors with the
industry insight and long-term commitment of strategic partners. Together, they provide a
strong foundation for delivering on our mission to build globally competitive life sciences
companies.
